Literature DB >> 11527633

Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance.

H Schmidt1, G von der Recke, S Illien, T Lewalter, R Schimpf, C Wolpert, H Becher, B Lüderitz, H Omran.   

Abstract

OBJECTIVES: The study was done to assess the prevalence of left atrial (LA) chamber and appendage thrombi in patients with atrial flutter (AFl) scheduled for electrophysiologic study (EPS), to evaluate the prevalence of thromboembolic complications after transesophageal echocardiographic (TEE)-guided restoration of sinus rhythm and to evaluate clinical risk factors for a thrombogenic milieu.
BACKGROUND: Recent studies showed controversial results on the prevalence of atrial thrombi and the risk of thromboembolism after restoring sinus rhythm in patients with AFl.
METHODS: Between 1995 and 1999, patients with AFl who were scheduled for EPS were included in the study. After transesophageal assessment of the left atrial appendage and exclusion of thrombi, an effective anticoagulation was initiated and patients underwent EPS within 24 h.
RESULTS: We performed 202 EPSs (radiofrequency catheter ablation, n = 122; overdrive stimulation, n = 64; electrical cardioversion, n = 16) in 139 consecutive patients with AFl. Fifteen patients with a thrombogenic milieu were identified. All of them had paroxysmal atrial fibrillation (AF). Transesophageal echocardiography revealed LA thrombi in two cases (1%). After EPS no thromboembolic complications were observed. Diabetes mellitus, arterial hypertension and a decreased left ventricular ejection fraction were found to be independent risk factors associated with a thrombogenic milieu.
CONCLUSIONS: The findings of a low prevalence of LA appendage thrombi (1%) in patients with AFl and a close correlation between a history of previous embolism and paroxysmal AF support the current guidelines that patients with pure AFl do not require anticoagulation therapy, whereas patients with AFl and paroxysmal AF should receive anticoagulation therapy. In addition, the presence of clinical risk factors should alert the physician to an increased likelihood for a thrombogenic milieu.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527633     DOI: 10.1016/s0735-1097(01)01463-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Successful thrombolysis in patient with right heart thromboembolism : a case report and literature overview.

Authors:  E Koenigshausen; K Magnusson; E G Vester
Journal:  Clin Res Cardiol       Date:  2007-08-14       Impact factor: 5.460

Review 3.  Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke.

Authors:  D J H McCabe; R D Rakhit
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

4.  Left Atrial Thrombus and Dense Spontaneous Contrast in Direct Oral Anticoagulant Therapy of Atrial Fibrillation: Insights from a Reference Center.

Authors:  Thiago Marques; Francisco Darrieux; Fábio Gouvêa; Leandro Garambone; Ana Paula Lindoso; João Lage; Luciana Sacilotto; Ana Lúcia Coimbra; Martina Pinheiro; Natália Olivetti; Sissy Lara; Carina Hardy; Guilherme Athayde; Denise Hachul; Cristiano Pisani; Tan Chen Wu; Maurício Scanavacca
Journal:  Arq Bras Cardiol       Date:  2022-09-23       Impact factor: 2.667

5.  Prediction of left atrial thrombi in patients with atrial tachyarrhythmias during warfarin administration: retrospective study in Hyogo College of Medicine.

Authors:  Hideyuki Kishima; Takanao Mine; Takeshi Kodani; Tohru Masuyama
Journal:  Heart Vessels       Date:  2015-05       Impact factor: 2.037

6.  Differences in Stroke or Systemic Thromboembolism Readmission Risk After Hospitalization for Atrial Fibrillation and Atrial Flutter.

Authors:  Harshith S Thyagaturu; Alexander Bolton; Sittinun Thangjui; Kashyap Shah; Bishesh Shrestha; Dinesh Voruganti; Daniel Katz
Journal:  Cureus       Date:  2022-04-05

7.  Cerebrovascular accidents differ between patients with atrial flutter and patients with atrial fibrillation.

Authors:  Jacek Staszewski; Anna Bilbin-Bukowska; Wojciech Szypowski; Marcin Mejer-Zahorowski; Adam Stępień
Journal:  Arch Med Sci       Date:  2019-07-18       Impact factor: 3.318

8.  Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting.

Authors:  Pak-Hei Chan; Chun-Ka Wong; Yukkee C Poh; Louise Pun; Wangie Wan-Chiu Leung; Yu-Fai Wong; Michelle Man-Ying Wong; Ming-Zher Poh; Daniel Wai-Sing Chu; Chung-Wah Siu
Journal:  J Am Heart Assoc       Date:  2016-07-21       Impact factor: 5.501

Review 9.  Review of the 2019 European Society of Cardiology Guidelines for the management of patients with supraventricular tachycardia: What is new, and what has changed?

Authors:  Sercan Okutucu; Bülent Görenek
Journal:  Anatol J Cardiol       Date:  2019-11       Impact factor: 1.596

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.